Itonis, Inc. (OTC Pink: ITNS) Soars 143% After Announcing “Emesyl Plus” Nasal Spray With Premium Hemp Oil

Spotlight Growth - Penny Stocks, Small Cap Stocks, Micro-Cap and Micro Cap Stocks, Stock Exchange, NASDAQ, Crypto, BitCoin, DogeCoin, Ai, Artificial Intelligence, Chat GPT, OpenAi, Open Ai, ASURE Software, Trending, Now, Breaking News, BioTech, Data, Analytics, Technology, Big Tech, Banking, SVB, Bank Closures, Failures, Finance, Stock Market News, WeBull, RobinHood, Reddit Traders, Trading, Investing, Investors, Investment, Investments, Day Trading, Real Estate, VC, Venture Capital, Private Equity, Firm, Firms, OTC Markets, Public, Private, OTCQB, GOOG, APPLE, Shareholders, Stakeholders, Shares, Finance Education, Blog, Articles, Consumer Goods, Pharma, Commodities, Precious Metals, Gold, Silver, Cannabis, CBD, Lithium, Electric Vehicles, Solar, Tesla, Charging, EV, Cloud Computing, Wall Street Bets, Sports Betting, Economy, Economics, IPO, Trade Ideas, Intellectual Property Rights, Private Placement, Crowd Funding, Fundraising, Meta, Metaverse, Web 3, Cyber, Cybersecurity, Cyber Security, Aircraft, VPN, Yahoo Finance, Benzinga, BarChart.

Itonis, Inc. (OTC Pink: ITNS) is engaged within the distribution of products across the medical and pharmaceutical industries. Shares of the medical distributor soared 142.86% during trading on Wednesday, September 26, 2018. Over the past month, Itonis has seen average daily volume of 585,967 shares. However, volume of 22.77 million shares or dollar volume of $38,709, exchanged hands during trading on Wednesday.

Shares of Itonis, Inc. surged on Wednesday, after the company announced a new homeopathic nasal spray called Emesyl Plus, which contains “premium hemp oil derived from hemp seeds from cannabis sativa plants.” The company notes that the product is also now available on Amazon.com, Inc. (NASDAQ: AMZN). National Homeopathic Labs is the manufacturer of the Emesyl and Emesyl Plus products, which are now being distributed with the help of Itonis. Here is the full press release detailing of the nasal spray:

Itonis, Inc. Press Release:

LAGUNA HILLS, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) — Itonis, Inc. (OTC PINKSHEETS: ITNS)

Itonis, Inc. is pleased to announce Emesyl® Plus, a new revolutionary homeopathic nasal spray containing Premium Hemp Oil derived from hemp seeds from Cannabis sativa plants. The product is immediately available for sale on Amazon, and can be found here: https://www.amazon.com/dp/B07H2Z9BHS.

Emesyl® Plus is used to help fortify your mind and body, target moderate changes in health, and to strengthen a foundation of overall wellness. As Emesyl® Plus includes the Emesyl® anti-nausea formula as well, it also offers all the same benefits as Emesyl®, the company’s flagship product used to treat nausea and nausea-like symptoms.

Emesyl® Plus is manufactured by National Homeopathic Labs, also the manufacturer of Emesyl®. National Homeopathic Labs is a cGMP, FDA registered contract manufacturer that has specialized in formula development and packaging of homeopathic, nutritional, cosmeceutal, and dietary supplements for over 25 years.

Itonis is also pleased to announce that Emesyl® Plus carries a two year expiration from the date of manufacture. The product is currently in the process of extended Stability testing for three year expiration, and an announcement will be made as soon as the additional Stability testing requirements are complete.

Additional information about Emesyl® Plus can be found on DailyMed, operated by the U.S. National Library of Medicine (NLM): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53db5df9-31f7-4f6c-bdd0-c7f516e867f2.

“We are very excited with the launch of Emesyl® Plus, and look forward to strong product demand in helping others to strengthen a foundation of overall wellness,” said Steve Pidliskey, Itonis’ Vice President. “We believe Emesyl® Plus will be a knockout winner in the marketplace.”

Meanwhile, our original Emesyl® Nausea Relief nasal spray continues to be sold by a reseller at Amazon.com (https://www.amazon.com/Itonis-Inc-Emesyl-Nausea-Relief/dp/B00U20H3KI/ref=sr_1_1_a_it?ie=UTF8&qid=1537974790&sr=8-1&keywords=Itonis%2C+Inc ) and at Walmart.com (https://www.walmart.com/ip/Emesyl-Nausea-Relief/792523063). It is also available directly from Itonis at https://www.emesyl.com/.

About Itonis, Inc.

Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. Please visit www.itonisholdings.com for additional information.

About National Homeopathic Labs.

Located in Las Vegas, Nevada, National Homeopathic Labs is a cGMP, FDA registered contract manufacturer that specializes in formula development and packaging of homeopathic, nutritional, cosmeceutal, and dietary supplements.

Safe Harbor:

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.

Itonis, Inc. (OTC Pink: ITNS) Soars 143% After Announcing “Emesyl Plus” Nasal Spray With Premium Hemp Oil

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

Vision Marine (NASDAQ: VMAR): An Innovative, Revenue-Producing Company Riding the Electric Boating Growth Trend

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

Telcoin (TEL) Continues to Demonstrate Fundamental Progress, Displaying Bullish Technical Setup

Grove Collaborative (NYSE: GROV) Expands Retail Distribution Footprint Into 2,200 Additional Stores

The Metaverse is Exploding in Popularity and Growth

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

Safe-T Group Ltd. (NASDAQ: SFET) to Participate at A.G.P.’s Virtual Emerging Growth Technology Conference on February 4, 2021

Nvidia Announces New Chip Specifically For Ethereum Mining

Sortis Holdings, Inc. (OTC Pink: SOHI) Announces Results for Second Quarter 2020

Medical Marijuana Coming Soon to Virginia

SushiSwap (SUSHI) Appropriates Uniswap’s Liquidity Pool by Preempting Native Token Release

Europe Shows Signs of Warming to SPACs

Singapore’s Journey to Becoming a Biotech Powerhouse

SeaStar Medical (NASDAQ: ICU) Earns Third FDA Breakthrough Device Designation for Selective Cytopheretic Device

Exploring What Led to a 3,000% Surge in Shares of Tempest Therapeutics (NASDAQ: TPST)

Vivos Therapeutics (NASDAQ: VVOS) Secures Strategic Alliances to Enhance Clear Aligner Offerings and Bolster Revenue Streams

Shares of Soleno Therapeutics (NASDAQ: SLNO) Surge Over 500% After Its DCCR Candidate Shows Promise in PWS Clinical Trials

Understanding EBITDA and Adjusted EBITDA: A View Into Asure’s (NASDAQ: ASUR) Recent Financial Performance

From Microsoft to Travel Tech: VCI Global’s (NASDAQ: VCIG) Expanding AI Horizons

Singapore’s Leap into the Future of Cell and Gene Therapies

Asure (NASDAQ: ASUR) Completes Capital Raise to Fuel High-Interest Debt Reduction, Craig-Hallum Analyst Praises Move and Estimates Bullish Outcome

Asure (NASDAQ: ASUR) Reports Massive 50% Y/Y Revenue Growth During Q2 2023, Raises $40 Million to Pay Off High-Interest Debt and Fund Acquisitions

Recent News

Singapore’s Journey to Becoming a Biotech Powerhouse

SeaStar Medical (NASDAQ: ICU) Earns Third FDA Breakthrough Device Designation for Selective Cytopheretic Device

Categories

Site Navigation